BPC-157 Compounding Legal Status: What Patients and Prescribers Need to Know

What is BPC-157's compounding status today?

BPC-157 has no approval and no place on either list of bulk substances that compounders may use [1][2][5].

• On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), BPC-157 appears in none of the three categories [2]. Category 1 is the group FDA says it generally will not act against compounders for when the conditions are met, so that policy does not reach BPC-157 [2].
• BPC-157 is also absent from FDA's list for outsourcing facilities, the large registered compounders that can distribute without a patient-specific prescription (list updated March 21, 2025) [5].

What exists instead is a draft. HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy for compounding with six peptides, BPC-157 among them, scheduled for Federal Register publication on October 30, 2026 with public comments open for two weeks after publication [3].

Did FDA ban BPC-157?

No. FDA has not banned BPC-157 by name; it is an unapproved substance whose compounding status is set by the bulk-substance rules and the draft policy described here [2].

The approval side is settled and separate: no FDA-approved drug contains BPC-157, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

What changed between 2023 and 2026?

BPC-157 sat in category 2 of FDA's significant-safety-risk policy from September 2023 until April 22, 2026 [6][4]. FDA's page on these substances, with content dated 04/22/2026, now lists it in a separate table headed 'nominated but withdrawn' rather than the active significant-safety-risk table, because the groups that nominated it for FDA's pharmacy bulks list withdrew their nominations [6][4].

The move off category 2 was not a finding of safety, and FDA's stated concerns remain on that page [6][4]. FDA wrote that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' and may have problems with peptide-related impurities and characterization of the active ingredient; the agency said it 'has identified no, or only limited, safety-related information for the proposed routes of administration' and 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [6].

What did the July 2026 advisory committee vote mean?

FDA's own reviewers proposed that BPC-157 not be added to the pharmacy bulks list, citing poor chemical characterization, little information on safety and immunogenicity, insufficient evidence that it works for ulcerative colitis (the use FDA evaluated), and the fact that several approved drugs already treat ulcerative colitis [1].

On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it, against the staff recommendation; news reports give the vote as 8 to 6 with 1 abstention [7][4]. That vote is advice only. BPC-157 is not on the list, and adding it requires formal rulemaking through a proposed rule, public comment and a final rule [7][4].

What does the draft October 2026 policy actually say?

HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA's list is developed through rulemaking, if the policy's conditions are met [3]. The conditions for BPC-157 are specific [4]:

• BPC-157 acetate only. FDA treats the free base and the acetate salt as two different bulk substances [1][4].
• Subcutaneous, intramuscular, oral or topical forms. Nasal, rectal and intravenous forms are not listed [4].
• A single active ingredient.
• Bulk substance from an FDA-registered manufacturer, with a valid certificate of analysis meeting a peptide testing standard.
• A label reading 'This is a compounded drug product. Not for resale.'
• A patient-specific prescription.
• Serious adverse events and quality problems reported to FDA MedWatch.
• Only an FDA 510(k)-cleared syringe as the co-packaged device.
• For oral forms, documentation of adequate bioavailability.

The draft is not an approval and does not put BPC-157 on any list. The notice states that it 'does not establish any rights for any person and is not binding on HHS or the public,' and HHS may revisit it, for example if a safety signal or product quality issue appears [4]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [4][3].

What has FDA said about safety?

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and found no human studies of the peptide given by mouth, subcutaneous injection, nasal spray or skin [1].

FDA's search of its adverse-event database through December 4, 2025 turned up 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused these [1].

In animal work, 28-day intramuscular studies showed BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1]. FDA also found no human pharmacokinetic data for oral, subcutaneous, nasal or skin use; after rectal enemas in two early studies the peptide was mostly undetectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

What human evidence exists, and where is it thin?

The published human record is small. A retrospective chart review included 17 patients who received knee injections of BPC-157, alone or with thymosin beta-4; 16 were reached for follow-up, and 11 of the 12 who received BPC-157 alone (91.6%) reported significant improvement, with no control group, no validated outcome tools and recalled results [10]. A single-arm pilot injected a total of 10 mg around the bladder wall in 12 women with interstitial cystitis; 10 reported complete symptom resolution and 2 about 80%, with no placebo and patient-rated outcomes [11]. A two-person pilot gave 10 mg intravenously on day 1 and 20 mg on day 2 with no measurable change in tested heart, liver, kidney, thyroid or glucose markers and no side effects reported — a sample too small to establish safety [12].

A 2026 systematic review searched to June 1, 2026 and found only 3 studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low; the reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [13]. There is no approved dose because there is no approved product; doses in the small human reports have ranged from 2 to 4 mg injected into the knee to 80 mg daily by enema in ulcerative colitis, and none of these is a recommended dose [1].

Does this affect athletes?

Yes, independently of the FDA question. WADA's Prohibited List names BPC-157 in S0 (non-approved substances), prohibited at all times, in and out of competition; the 2026 List took effect January 1, 2026 [8]. WADA first named it as an example under S0 in the 2022 List after a re-evaluation, and it stays named in the 2027 List approved September 10, 2026 [14][15].

What about compounded and research-labeled products?

FDA says compounded drugs are not FDA-approved, so it does not review their safety, effectiveness or quality before they reach patients [9]. FDA has also noted websites selling BPC-157, alone or blended with TB-500, as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only and not for human or veterinary use'; those products are not FDA-approved drugs [1]. The draft HHS policy, by contrast, is limited to BPC-157 acetate in the forms and under the conditions listed above, and it is non-binding and open to change [4].